Chinese Firm Buying Israel's Alma Lasers for $240 Million

Second huge exit taking shape this month, following $480 million deal for Prolor Biotech.

The Shanghai Fosun Pharma group says it is purchasing Israeli medical and cosmetic laser equipment maker Alma Lasers for $240 million.

This is the second major transaction involving an Israeli company within a few days, following the sale of Prolor Biotech to Nasdaq-listed OPKO Health for $480 million (which remains contingent on certain closing terms).

Alma Lasers, which was formed by a merger between MSQ, an Israeli company headed by Ziv Karni, and U.S.-based Orion Lasers, operates out of the Caesarea industrial park. It develops, makes and sells laser devices, light-based, radiofrequency and ultrasound devices for cosmetic and medical applications to treat conditions including acne, psoriasis, fungal infections of the nails and varicose veins.

Since 2006 the merged company has been under the control of international private equity firm TA Associates, which has invested $90 million in Alma Lasers at a company value of $140 million.

TA Associates currently holds a 73% interest in the company while Karni owns 16.5%.

Fosun Pharma was registered several months ago on the Hong Kong Stock Exchange, where it currently trades at a market value of $4.2 billion.

Nimrod Glickman